Kayentis Chooses SFR Business Team for its "Machine to Machine" Roaming in Close to 250 Countries
Grenoble, 1st Septembre 2015 – Kayentis, French software provider specialized in solutions for clinical pharmaceutical trials, has just chosen SFR Business Team for its M2M roaming in close to 250 countries.
Kayentis has been a leading name in solutions for clinical trials for 10 years. 18 months ago, in addition to its emblematic digital pen device, the company launched a solution enabling patient data to be entered by tablet.
In order to implement its solutions in the international market, Kayentis wished to approach a major player in the telecoms sector and thus chose SFR Business Team. The partnership agreement between the two companies authorises M2M roaming in close to 250 countries.
This solution guarantees permanent connectivity between the clinic investigation centres, where the data is collected, the Kayentis database servers and the portal provided for its customers.
It has already been implemented in more than 40 countries, via two eCOA projects (eClinical Outcome Assessment) for phase III clinical studies, linked with one of the five largest pharmaceutical laboratories in the world.
Working with SFR Business Team has enabled Kayentis to lean on one of the leading names in MtoM solutions worldwide and strengthen the brand’s ambitious plans for development.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Full Phase IIIb BATURA Trial Results Show Airsupra Cuts Severe Exacerbations by 47% in Mild Asthma
May 20th 2025Results from the pivotal BATURA trial show that Airsupra (albuterol/budesonide) significantly outperformed albuterol monotherapy in reducing severe asthma exacerbations and systemic corticosteroid exposure, reinforcing its role as a next-generation, anti-inflammatory rescue therapy for mild asthma patients.
